# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sun Yat-sen (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET016-SYN
- Date: 2026-10-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Wen-Li Huang, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Before cycle 8: restaging CT, side effects, low magnesium, and the plan for maintenance. **S**

## History of present illness

Mr. Sun returns before his eighth and last cycle of chemotherapy, five weeks after his preventive visit. Cycles 4 to 7 were given on schedule; the cold he had during cycle 5 settled without fever. For two weeks he has had a light tingling in his fingertips that does not affect buttoning or writing. He has had muscle cramps in his calves at night. He has no diarrhea, rash, cough or breathlessness, and no hearing change. His weight is steady. The ache under his ribs has gone most days. His HIV test from the preventive visit was negative. The restaging CT and HBV DNA four days ago are back. **S**

| Element | Detail |
|---|---|
| Cycles | Seven, on schedule |
| New symptoms | Fingertip tingling for two weeks; night cramps in the calves |
| Immune-related symptoms | None |
| Weight | Steady |
| Results | HIV test negative; restaging CT and HBV DNA back |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired after infusions; weight 59.6 kg; no fever |
| Musculoskeletal | Positive | Night cramps in both calves |
| Neurological | Positive | Light tingling in the fingertips; no weakness; buttons and writes normally |
| Ears, nose, mouth, and throat | Negative | No tinnitus or hearing change |
| Gastrointestinal | Negative | Ache mostly gone; nausea mild after infusions; no diarrhea |
| Respiratory | Negative | No cough or breathlessness |

6 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a day **S**
- Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycle **S**
- Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycle **S**
- Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycle **S**
- Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**
- Magnesium oxide 400 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 59.6 kg; BMI 21.9 kg/m². All vital signs are synthetic.

White cells: 4.3 10*3/uL; Neutrophils: 2.1 10*3/uL; Hemoglobin: 10.7 g/dL (low); Platelets: 176 10*3/uL; Sodium: 137 mmol/L; Potassium: 4.1 mmol/L; Creatinine: 0.95 mg/dL; eGFR: 93 mL/min/1.73 m²; Glucose: 96 mg/dL; Magnesium: 1.6 mg/dL (low); Albumin: 3.7 g/dL; Total bilirubin: 0.6 mg/dL; Alkaline phosphatase: 141 U/L (high); AST: 31 U/L; ALT: 28 U/L; TSH: 3.1 mIU/L; CA 19-9: 121 U/mL (high); PHQ-9: 4; ECOG performance status: 1. All results are synthetic.

## Change since baseline

- White cells: 7.9 10*3/uL at baseline, 4.3 10*3/uL at this visit **S**
- Hemoglobin: 12.6 g/dL (low) at baseline, 10.7 g/dL (low) at this visit **S**
- Platelets: 342 10*3/uL at baseline, 176 10*3/uL at this visit **S**
- Sodium: 137 mmol/L at baseline, 137 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.1 mmol/L at this visit **S**
- Creatinine: 0.86 mg/dL at baseline, 0.95 mg/dL at this visit **S**
- eGFR: 101 mL/min/1.73 m² at baseline, 93 mL/min/1.73 m² at this visit **S**
- Glucose: 98 mg/dL at baseline, 96 mg/dL at this visit **S**
- Albumin: 3.4 g/dL (low) at baseline, 3.7 g/dL at this visit **S**
- Total bilirubin: 0.9 mg/dL at baseline, 0.6 mg/dL at this visit **S**
- Alkaline phosphatase: 212 U/L (high) at baseline, 141 U/L (high) at this visit **S**
- AST: 48 U/L (high) at baseline, 31 U/L at this visit **S**
- ALT: 41 U/L at baseline, 28 U/L at this visit **S**
- CA 19-9: 412 U/mL (high) at baseline, 121 U/mL (high) at this visit **S**
- ECOG performance status: 1 at baseline, 1 at this visit **S**

## Immunizations given today

- Recombinant zoster vaccine, first of two doses **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin, well; blood pressure 124/78, pulse 80; weight 59.6 kg; no jaundice |
| Abdomen | Liver edge 2 cm below the right costal margin; no ascites |
| Neurological | Vibration slightly reduced at the fingertips; light touch, strength and reflexes normal |
| Skin | No rash; port site clean |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Gallbladder adenocarcinoma, stage IVB, on chemoimmunotherapy** (C23). Restaging CT: mass 4.9 cm; nodes and peritoneal nodules smaller still; no new lesions. The sum of target lesions has fallen 33% from baseline: partial response by RECIST. CA 19-9 121 U/mL. Grade 1 sensory neuropathy from cisplatin, not limiting function; magnesium 1.6 mg/dL with night cramps, from cisplatin; hemoglobin 10.7 g/dL. TSH 3.1. **S**
   - Cycle 8 today; cisplatin continued because the neuropathy is grade 1 and this is the last cycle.
   - Magnesium oxide 400 mg daily; magnesium with each dose.
   - Durvalumab 1,500 mg every 4 weeks from four weeks after today, until progression or unacceptable toxicity.
   - Restaging CT every 2 to 3 months.
   - Recombinant zoster vaccine today.
2. **Peritoneal metastases** (C78.6). Smaller; no ascites. **S**
   - Followed on restaging CT.
3. **Resolved hepatitis B infection** (Z86.19). HBV DNA undetectable four days ago; ALT 28 U/L. **S**
   - HBV DNA and ALT every 3 months on durvalumab and for 6 to 12 months after treatment.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | CT of the chest, abdomen and pelvis | At staging, then every 2 to 3 months on treatment | Completed today | Four days ago: mass 4.9 cm; partial response, sum down 33% from baseline; no new lesions |
| Laboratory | CA 19-9 (and CEA when raised) | At diagnosis, then with each cycle or restaging | Completed today | CA 19-9 121 U/mL |
| Laboratory | Blood count with neutrophils | Before every dose (days 1 and 8) | Completed today | White cells 4.3, neutrophils 2.1, hemoglobin 10.7 g/dL, platelets 176 |
| Laboratory | Creatinine and eGFR | Before every dose (days 1 and 8) | Completed today | Creatinine 0.95 mg/dL, eGFR 93 |
| Laboratory | Magnesium and potassium | Before every dose (days 1 and 8) | Completed today | Magnesium 1.6 mg/dL (low), potassium 4.1 mmol/L, sodium 137 mmol/L; magnesium oxide started |
| Laboratory | Liver tests (bilirubin, alkaline phosphatase, AST, ALT, albumin) | Before every dose (days 1 and 8) | Completed today | Bilirubin 0.6 mg/dL, alkaline phosphatase 141, AST 31, ALT 28 U/L, albumin 3.7 g/dL |
| Laboratory | TSH | Baseline, then every 4 to 6 weeks on durvalumab | Completed today | 3.1 mIU/L |
| Laboratory | Glucose | Baseline, then with each pre-dose chemistry panel on durvalumab | Completed today | 96 mg/dL |
| Laboratory | HBV DNA and ALT (resolved hepatitis B) | Every 3 months during treatment and for 6 to 12 months after | Completed today | HBV DNA undetectable four days ago; ALT 28 U/L |
| Medication safety | Immune-related side effects (diarrhea, rash, cough or breathlessness, fatigue, endocrine symptoms) | Every visit | Completed today | None |
| Medication safety | Chemotherapy side effects: nausea, fatigue, neuropathy, hearing | Every visit | Completed today | Grade 1 sensory neuropathy; night cramps with low magnesium |
| Examination | Hearing (cisplatin) | Baseline before cisplatin, then by symptoms each cycle | Completed today | No hearing symptoms; the audiogram is not needed unless symptoms appear |
| Survey | ECOG performance status | Every visit | Completed today | ECOG 1 |
| Examination | Weight and nutrition | Every visit | Completed today | 59.6 kg, within 0.4 kg of the start of treatment |
| Survey | Pain | Every visit | Completed today | 0 to 1 of 10 |
| Survey | Distress and depression (PHQ-9) | At each change in treatment or status | Completed today | PHQ-9 4 |
| Referral | Specialist palliative care | From the diagnosis of advanced cancer | Completed today | Seen every 3 to 4 weeks |
| Self-management | Goals of care and advance care planning | At diagnosis and at each change in treatment | Completed today | Goals reviewed with the move to maintenance; agent named at the preventive visit |
| Self-management | Vaccination review | Yearly and during treatment | Completed today | Influenza, COVID-19 and PCV20 at the preventive visit; first recombinant zoster dose today |

## Goal progress

- Tissue diagnosis and complete staging within four weeks of the first visit. Outcome by 2026-06-01: Biopsy diagnosis in nine days and staging complete by laparoscopy in about three and a half weeks. **S**
- Right upper abdominal pain at 3 of 10 or less, with full days of work possible (ECOG 0 to 1). Outcome by 2026-10-26: Ache 0 to 2 of 10 on acetaminophen as needed; ECOG 1 throughout. **S**
- Weight held within 2 kg of the weight at the start of treatment. Outcome by 2026-10-26: 60.0 kg at cycle 1 and 59.6 kg at cycle 8. **S**
- Goals of care and a health care agent documented, and revisited as treatment changes. Outcome by 2026-09-21: Agent named and goals recorded with palliative care and at the preventive visit. **S**
- Complete first-line chemoimmunotherapy without grade 3 or higher toxicity. Outcome by 2026-10-26: Seven cycles given by the last visit with grade 1 toxicity only; the eighth started that day. **S**

## Medication changes

- Started: Magnesium oxide 400 mg oral tablet, one tablet by mouth daily **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026), National Comprehensive Cancer Network
- Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1) (2022), NEJM Evidence
- Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention

## Follow-up

- Cycle 8 day 8 next week. Durvalumab maintenance every 4 weeks from four weeks after today. Second zoster dose in one to two months. Restaging CT in 2 to 3 months. **S**

